Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Acquisition of equity interests and conversion into a subsidiaryDisclosing companyROHTO PHARMACEUTICAL CO.,LTD.
Execution Date / Effective Date8 July 2026 (completed)
Target company
Import and sale of cosmetics and miscellaneous goods, and marketing
Location Novi Sad, Republic of SerbiaShare capital Not disclosedDate of incorporation 2011
Impact on Business Performance
The impact of this transaction on consolidated results for the current fiscal year is immaterial
Procedures and assumptions
Management structure after acquisitionThe company was made a group company of Rohto Pharmaceutical. Its trade name, representative and treatment of employees are not disclosed
| Item | Details |
|---|---|
| Transaction name | Acquisition of equity interests and conversion into a subsidiary |
| Name of the Subject Company | Magic Cod d.o.o. |
| Business Description of the Subject Company | Import and sale of cosmetics and miscellaneous goods, and marketing |
| Location of the Subject Company | Novi Sad, Republic of Serbia |
| Capital Stock of the Subject Company | Not disclosed |
| Date of Establishment of the Subject Company | 2011 |
| Impact on Business Performance | The impact of this transaction on consolidated results for the current fiscal year is immaterial |
| Execution Date / Effective Date | 8 July 2026 (completed) |
| Management structure after acquisition | The company was made a group company of Rohto Pharmaceutical. Its trade name, representative and treatment of employees are not disclosed |
Items this document does not state (23)
Counterparty nameNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand its overseas business, the Company will leverage the target company's sales network and customer base in Europe to strengthen its sales structure and pursue integrated management of marketing initiatives, product development and brand strategy based on local market needs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.